


REMARKS

Claims 1-16 and 21-24 are pending in the present application. Claims 17-20 and 25-27 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claim 4 has been amended to correct an obvious error. Claims 22-24 have been amended to eliminate multiple dependency. Applicants have also amended the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: 2/9/2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1467
Facsimile: 919-483-7988